Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1999 1
2013 1
2014 1
2019 2
2020 1
2021 1
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.
Martínez-Domínguez SJ, García-Mateo S, Gargallo-Puyuelo CJ, Gallego-Llera B, Callau P, Mendi C, Arroyo-Villarino MT, Simón-Marco MÁ, Ampuero J, Gomollón F. Martínez-Domínguez SJ, et al. Among authors: arroyo villarino mt. Inflamm Bowel Dis. 2023 Aug 22:izad175. doi: 10.1093/ibd/izad175. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37607330
Lifestyle Can Exert a Significant Impact on the Development of Metabolic Complications and Quality Life in Patients with Inflammatory Bowel Disease.
García-Mateo S, Martínez-Domínguez SJ, Gargallo-Puyuelo CJ, Arroyo Villarino MT, Laredo De La Torre V, Gallego B, Alfambra E, Gomollón F. García-Mateo S, et al. Among authors: arroyo villarino mt. Nutrients. 2023 Sep 14;15(18):3983. doi: 10.3390/nu15183983. Nutrients. 2023. PMID: 37764769 Free PMC article.
Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.
Martínez-Domínguez SJ, García-Mateo S, Gargallo-Puyuelo CJ, Gallego Llera B, Refaie E, Callau P, Mendi C, Baptista PM, Hernández Ainsa M, Arroyo-Villarino MT, López de la Cruz J, Martínez-García J, Alfambra E, Simón Marco MÁ, Ampuero J, Gomollón F. Martínez-Domínguez SJ, et al. Among authors: arroyo villarino mt. Eur J Intern Med. 2024 Feb;120:99-106. doi: 10.1016/j.ejim.2023.10.019. Epub 2023 Oct 21. Eur J Intern Med. 2024. PMID: 37872034
Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease.
Refaie E, García Mateo S, Martínez Domínguez SJ, Gargallo-Puyuelo CJ, Lario Quilez L, Carrera-Lasfuentes P, Arroyo Villarino MT, Gomollón García F. Refaie E, et al. Among authors: arroyo villarino mt. Gastroenterol Hepatol. 2022 Feb;45(2):114-122. doi: 10.1016/j.gastrohep.2021.03.012. Epub 2021 May 21. Gastroenterol Hepatol. 2022. PMID: 34023473 Free PMC article.
Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease.
Elosua González A, Sanz Segura P, Oyón Lara D, López García S, Arroyo Villarino MT, Alcalá Escriche MJ, Ollero Domenche L, Rodríguez Gutiérrez C, Nantes Castillejo Ó. Elosua González A, et al. Among authors: arroyo villarino mt. Med Clin (Barc). 2020 Jun 26;154(12):475-480. doi: 10.1016/j.medcli.2019.07.025. Epub 2019 Nov 27. Med Clin (Barc). 2020. PMID: 31785803 English, Spanish.
Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs.
Martínez-Domínguez SJ, García-Mateo S, Sainz-Arnal P, Martínez-García J, Gallego-Llera B, Lozano-Limones MJ, Hidalgo S, Gargallo-Puyuelo CJ, Latre-Santos M, Nocito-Colon MML, Martínez-Lostao L, Refaie E, Arroyo-Villarino MT, Del Rio-Nechaevsky M, Ramirez-Labrada A, Pardo J, Gomollón F, Baptista PM. Martínez-Domínguez SJ, et al. Among authors: arroyo villarino mt. Sci Rep. 2023 Dec 27;13(1):23061. doi: 10.1038/s41598-023-50537-y. Sci Rep. 2023. PMID: 38155275 Free PMC article.
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study.
Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E, Gisbert JP; Spanish GETECCU group (ENEIDA Project). Guerra I, et al. Among authors: arroyo villarino mt. J Crohns Colitis. 2019 Dec 10;13(12):1492-1500. doi: 10.1093/ecco-jcc/jjz094. J Crohns Colitis. 2019. PMID: 31063540
Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata.
Lanas A, Carrera-Lasfuentes P, García-Rodríguez LA, García S, Arroyo-Villarino MT, Ponce J, Bujanda L, Calleja JL, Polo-Tomas M, Calvet X, Feu F, Perez-Aisa A. Lanas A, et al. Among authors: arroyo villarino mt. Scand J Gastroenterol. 2014 Oct;49(10):1181-90. doi: 10.3109/00365521.2014.950694. Epub 2014 Aug 21. Scand J Gastroenterol. 2014. PMID: 25144754
Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial.
Lanas A, Polo-Tomas M, García-Rodríguez LA, García S, Arroyo-Villarino MT, Ponce J, Bujanda L, Calleja JL, Calvet X, Feu F, Perez-Aisa A, Sung JJ. Lanas A, et al. Among authors: arroyo villarino mt. Scand J Gastroenterol. 2013 Mar;48(3):285-94. doi: 10.3109/00365521.2012.758764. Epub 2013 Jan 8. Scand J Gastroenterol. 2013. PMID: 23298283
13 results